Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus Anlotinib in HRR-mutated advanced solid tumors
NCT04764084Phase 1Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niraparib and anlotinib in breast cancer, cholangiocarcinoma (CCA), gastric adenocarcinoma and 1 more, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
niraparibanlotinib
03
Conditions
breast cancercholangiocarcinoma (CCA)gastric adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04764084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764084.